Management of Neuromuscular Blocking Agents and Their Antagonism (NMBA_periop)

Free University of Brussels (ULB)

Status: Enrolling

Conditions: Neuromuscular Monitoring; Neuromuscular Blocking Agents

Treatments: Drug: Neuromuscular Blocking Agent

Study type: Observational

Funder types: Other

Identifiers

NCT06238219

SRB2024007

Details and patient eligibility

About

Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023.

Research hypothesis:

Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients undergoing surgery with use of neuromuscular blocking agents at our institution

Exclusion criteria

• Incomplete electronic anesthesia record

Trial design

3,000 participants in 1 patient group

NMBA cohort

Description:

Patients undergoing surgery under general anesthesia with use of neuromuscular blocking agents

Treatment:

Drug: Neuromuscular Blocking Agent